JP2019504009A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019504009A5 JP2019504009A5 JP2018531219A JP2018531219A JP2019504009A5 JP 2019504009 A5 JP2019504009 A5 JP 2019504009A5 JP 2018531219 A JP2018531219 A JP 2018531219A JP 2018531219 A JP2018531219 A JP 2018531219A JP 2019504009 A5 JP2019504009 A5 JP 2019504009A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- cyanopyrrolidin
- carboxamide
- compound
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 35
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 230000007812 deficiency Effects 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- -1 cyano, hydroxyl Chemical group 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 239000011737 fluorine Substances 0.000 claims 6
- 229910052731 fluorine Inorganic materials 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 125000004043 oxo group Chemical group O=* 0.000 claims 5
- 208000011580 syndromic disease Diseases 0.000 claims 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 4
- 125000004450 alkenylene group Chemical group 0.000 claims 4
- 208000008955 Mucolipidoses Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- KINAZPSFJPPTNP-UHFFFAOYSA-N 1-benzyl-N-[(1-cyanopyrrolidin-3-yl)methyl]indazole-3-carboxamide Chemical compound C(C1=CC=CC=C1)N1N=C(C2=CC=CC=C12)C(=O)NCC1CN(CC1)C#N KINAZPSFJPPTNP-UHFFFAOYSA-N 0.000 claims 2
- 206010058892 Carnitine deficiency Diseases 0.000 claims 2
- 208000002155 Cytochrome-c Oxidase Deficiency Diseases 0.000 claims 2
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 claims 2
- 201000002169 Mitochondrial myopathy Diseases 0.000 claims 2
- 208000001769 Multiple Acyl Coenzyme A Dehydrogenase Deficiency Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 208000006443 lactic acidosis Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 102000045222 parkin Human genes 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000016505 systemic primary carnitine deficiency disease Diseases 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- XRKWRSYZFZXPNK-GFCCVEGCSA-N (3R)-3-[[(5-phenyl-1,3-thiazol-2-yl)amino]methyl]pyrrolidine-1-carbonitrile Chemical compound C1(=CC=CC=C1)C1=CN=C(S1)NC[C@@H]1CN(CC1)C#N XRKWRSYZFZXPNK-GFCCVEGCSA-N 0.000 claims 1
- QTAQRVFBNSFBTI-GFCCVEGCSA-N (3R)-3-[[[7-(1H-pyrazol-4-yl)quinazolin-2-yl]amino]methyl]pyrrolidine-1-carbonitrile Chemical compound N1N=CC(=C1)C1=CC=C2C=NC(=NC2=C1)NC[C@@H]1CN(CC1)C#N QTAQRVFBNSFBTI-GFCCVEGCSA-N 0.000 claims 1
- CZPJNEFJNYKUES-ZDUSSCGKSA-N (3S)-3-[[(4-phenylpyrimidin-2-yl)amino]methyl]pyrrolidine-1-carbonitrile Chemical compound C1(=CC=CC=C1)C1=NC(=NC=C1)NC[C@H]1CN(CC1)C#N CZPJNEFJNYKUES-ZDUSSCGKSA-N 0.000 claims 1
- XRKWRSYZFZXPNK-LBPRGKRZSA-N (3S)-3-[[(5-phenyl-1,3-thiazol-2-yl)amino]methyl]pyrrolidine-1-carbonitrile Chemical compound C1(=CC=CC=C1)C1=CN=C(S1)NC[C@H]1CN(CC1)C#N XRKWRSYZFZXPNK-LBPRGKRZSA-N 0.000 claims 1
- VYAVKGQLSHJAKT-STQMWFEESA-N (3aR,6aS)-4-oxo-5-(5-phenyl-1,3-thiazol-2-yl)-3,3a,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrole-2-carbonitrile Chemical compound O=C1[C@@H]2[C@H](CN1C=1SC(=CN=1)C1=CC=CC=C1)CN(C2)C#N VYAVKGQLSHJAKT-STQMWFEESA-N 0.000 claims 1
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- JZUCLLKLEMMQAS-HWKANZROSA-N (E)-N-[(1-cyanopyrrolidin-3-yl)methyl]-3-(2-fluoro-4-methoxyphenyl)prop-2-enamide Chemical compound C(#N)N1CC(CC1)CNC(\C=C\C1=C(C=C(C=C1)OC)F)=O JZUCLLKLEMMQAS-HWKANZROSA-N 0.000 claims 1
- ITRNJIHJJWXGBV-UHFFFAOYSA-N 1-(3-benzylphenyl)-3-[(1-cyanopyrrolidin-3-yl)methyl]urea Chemical compound C(C1=CC=CC=C1)C=1C=C(C=CC=1)NC(=O)NCC1CN(CC1)C#N ITRNJIHJJWXGBV-UHFFFAOYSA-N 0.000 claims 1
- WOLDJIHMNJCNBH-UHFFFAOYSA-N 1-(3-chlorophenyl)-3-[(1-cyanopyrrolidin-3-yl)methyl]urea Chemical compound ClC=1C=C(C=CC=1)NC(=O)NCC1CN(CC1)C#N WOLDJIHMNJCNBH-UHFFFAOYSA-N 0.000 claims 1
- KPIDBNWWWTWMBH-CQSZACIVSA-N 1-(3-cyanophenyl)-N-[[(3R)-1-cyanopyrrolidin-3-yl]methyl]imidazole-4-carboxamide Chemical compound C(#N)C=1C=C(C=CC=1)N1C=NC(=C1)C(=O)NC[C@@H]1CN(CC1)C#N KPIDBNWWWTWMBH-CQSZACIVSA-N 0.000 claims 1
- GUDNWIAYUBLOGW-CQSZACIVSA-N 1-(4-cyanophenyl)-N-[[(3R)-1-cyanopyrrolidin-3-yl]methyl]imidazole-4-carboxamide Chemical compound C(#N)C1=CC=C(C=C1)N1C=NC(=C1)C(=O)NC[C@@H]1CN(CC1)C#N GUDNWIAYUBLOGW-CQSZACIVSA-N 0.000 claims 1
- GBJREHGFNWGHMH-UHFFFAOYSA-N 1-[(1-cyanopyrrolidin-3-yl)methyl]-3-(2,4-dichlorophenyl)urea Chemical compound C(#N)N1CC(CC1)CNC(=O)NC1=C(C=C(C=C1)Cl)Cl GBJREHGFNWGHMH-UHFFFAOYSA-N 0.000 claims 1
- QNPZPLVZKIOXGN-UHFFFAOYSA-N 1-[(1-cyanopyrrolidin-3-yl)methyl]-3-(2-fluoro-5-methylphenyl)urea Chemical compound C(#N)N1CC(CC1)CNC(=O)NC1=C(C=CC(=C1)C)F QNPZPLVZKIOXGN-UHFFFAOYSA-N 0.000 claims 1
- RWLCHIZFNSNKED-UHFFFAOYSA-N 1-[(1-cyanopyrrolidin-3-yl)methyl]-3-[4-(trifluoromethyl)phenyl]urea Chemical compound C(#N)N1CC(CC1)CNC(=O)NC1=CC=C(C=C1)C(F)(F)F RWLCHIZFNSNKED-UHFFFAOYSA-N 0.000 claims 1
- IOBLTEUPRJUINX-UHFFFAOYSA-N 1-benzyl-N-[(1-cyanopyrrolidin-3-yl)methyl]-5-methylpyrazole-3-carboxamide Chemical compound C(C1=CC=CC=C1)N1N=C(C=C1C)C(=O)NCC1CN(CC1)C#N IOBLTEUPRJUINX-UHFFFAOYSA-N 0.000 claims 1
- KESUWHZQFPDSAF-OAHLLOKOSA-N 1-benzyl-N-[[(3R)-1-cyanopyrrolidin-3-yl]methyl]imidazole-4-carboxamide Chemical compound C(C1=CC=CC=C1)N1C=NC(=C1)C(=O)NC[C@@H]1CN(CC1)C#N KESUWHZQFPDSAF-OAHLLOKOSA-N 0.000 claims 1
- ZXVWNENATYDNBQ-UHFFFAOYSA-N 2-[1-(1-cyanopyrrolidin-3-yl)ethylamino]-1,3-benzothiazole-6-carbonitrile Chemical compound C(#N)N1CC(CC1)C(C)NC=1SC2=C(N=1)C=CC(=C2)C#N ZXVWNENATYDNBQ-UHFFFAOYSA-N 0.000 claims 1
- KKOVOFAIBOKHBV-LLVKDONJSA-N 3-(2-chlorophenyl)-N-[[(3R)-1-cyanopyrrolidin-3-yl]methyl]-1,2-oxazole-5-carboxamide Chemical compound ClC1=C(C=CC=C1)C1=NOC(=C1)C(=O)NC[C@@H]1CN(CC1)C#N KKOVOFAIBOKHBV-LLVKDONJSA-N 0.000 claims 1
- ZFIDAESINVCFIU-LLVKDONJSA-N 3-(3-chlorophenyl)-N-[[(3R)-1-cyanopyrrolidin-3-yl]methyl]-1,2-oxazole-5-carboxamide Chemical compound ClC=1C=C(C=CC=1)C1=NOC(=C1)C(=O)NC[C@@H]1CN(CC1)C#N ZFIDAESINVCFIU-LLVKDONJSA-N 0.000 claims 1
- JHHBWYNMUIATMU-LLVKDONJSA-N 3-(4-chlorophenyl)-N-[[(3R)-1-cyanopyrrolidin-3-yl]methyl]-1,2-oxazole-5-carboxamide Chemical compound ClC1=CC=C(C=C1)C1=NOC(=C1)C(=O)NC[C@@H]1CN(CC1)C#N JHHBWYNMUIATMU-LLVKDONJSA-N 0.000 claims 1
- UCGYLXZVQNTFRU-UHFFFAOYSA-N 3-[(1-cyanopyrrolidin-3-yl)methylamino]-N-methylisoquinoline-6-carboxamide Chemical compound C(#N)N1CC(CC1)CNC=1N=CC2=CC=C(C=C2C=1)C(=O)NC UCGYLXZVQNTFRU-UHFFFAOYSA-N 0.000 claims 1
- UEBMHGLLMLHGJO-UHFFFAOYSA-N 3-[(1-cyanopyrrolidin-3-yl)methylamino]isoquinoline-6-carbonitrile Chemical compound C(#N)N1CC(CC1)CNC=1N=CC2=CC=C(C=C2C=1)C#N UEBMHGLLMLHGJO-UHFFFAOYSA-N 0.000 claims 1
- PYUGKMVIOCPOBN-UHFFFAOYSA-N 3-[(isoquinolin-1-ylamino)methyl]pyrrolidine-1-carbonitrile Chemical compound C1(=NC=CC2=CC=CC=C12)NCC1CN(CC1)C#N PYUGKMVIOCPOBN-UHFFFAOYSA-N 0.000 claims 1
- YOKSHJPDBNAERK-UHFFFAOYSA-N 3-[(quinolin-2-ylamino)methyl]pyrrolidine-1-carbonitrile Chemical compound N1=C(C=CC2=CC=CC=C12)NCC1CN(CC1)C#N YOKSHJPDBNAERK-UHFFFAOYSA-N 0.000 claims 1
- JYYXDFOTOBXNPH-UHFFFAOYSA-N 3-[1-(isoquinolin-3-ylamino)ethyl]pyrrolidine-1-carbonitrile Chemical compound C1=NC(=CC2=CC=CC=C12)NC(C)C1CN(CC1)C#N JYYXDFOTOBXNPH-UHFFFAOYSA-N 0.000 claims 1
- NNGLYZOCCYHEFK-UHFFFAOYSA-N 3-[1-[[6-(1H-pyrazol-4-yl)-1,3-benzothiazol-2-yl]amino]ethyl]pyrrolidine-1-carbonitrile Chemical compound N1N=CC(=C1)C1=CC2=C(N=C(S2)NC(C)C2CN(CC2)C#N)C=C1 NNGLYZOCCYHEFK-UHFFFAOYSA-N 0.000 claims 1
- UOADHNIYFIKIMN-UHFFFAOYSA-N 3-[1-[[6-(5-methyl-1,2-oxazol-4-yl)-1,3-benzothiazol-2-yl]amino]ethyl]pyrrolidine-1-carbonitrile Chemical compound CC1=C(C=NO1)C1=CC2=C(N=C(S2)NC(C)C2CN(CC2)C#N)C=C1 UOADHNIYFIKIMN-UHFFFAOYSA-N 0.000 claims 1
- JZUUVVQTEQTTBW-UHFFFAOYSA-N 3-[[(3-phenylpyridin-2-yl)amino]methyl]pyrrolidine-1-carbonitrile Chemical compound C1(=CC=CC=C1)C=1C(=NC=CC=1)NCC1CN(CC1)C#N JZUUVVQTEQTTBW-UHFFFAOYSA-N 0.000 claims 1
- FOFOVGZDYKHDMB-UHFFFAOYSA-N 3-[[(4-phenylpyridin-2-yl)amino]methyl]pyrrolidine-1-carbonitrile Chemical compound C1(=CC=CC=C1)C1=CC(=NC=C1)NCC1CN(CC1)C#N FOFOVGZDYKHDMB-UHFFFAOYSA-N 0.000 claims 1
- CZPJNEFJNYKUES-UHFFFAOYSA-N 3-[[(4-phenylpyrimidin-2-yl)amino]methyl]pyrrolidine-1-carbonitrile Chemical compound C1(=CC=CC=C1)C1=NC(=NC=C1)NCC1CN(CC1)C#N CZPJNEFJNYKUES-UHFFFAOYSA-N 0.000 claims 1
- MJYAYUHQVOKQOU-UHFFFAOYSA-N 3-[[(5-phenylpyridin-2-yl)amino]methyl]pyrrolidine-1-carbonitrile Chemical compound C1(=CC=CC=C1)C=1C=CC(=NC=1)NCC1CN(CC1)C#N MJYAYUHQVOKQOU-UHFFFAOYSA-N 0.000 claims 1
- LARDRORDJPWVJU-UHFFFAOYSA-N 3-[[(6-fluoro-1,3-benzothiazol-2-yl)amino]methyl]pyrrolidine-1-carbonitrile Chemical compound FC1=CC2=C(N=C(S2)NCC2CN(CC2)C#N)C=C1 LARDRORDJPWVJU-UHFFFAOYSA-N 0.000 claims 1
- OKPFVCAOSFLUBO-UHFFFAOYSA-N 3-[[(6-phenylpyridin-2-yl)amino]methyl]pyrrolidine-1-carbonitrile Chemical compound C1(=CC=CC=C1)C1=CC=CC(=N1)NCC1CN(CC1)C#N OKPFVCAOSFLUBO-UHFFFAOYSA-N 0.000 claims 1
- BONIFODIXPLUFS-UHFFFAOYSA-N 3-[[3-(1,3-dimethylpyrazol-4-yl)anilino]methyl]pyrrolidine-1-carbonitrile Chemical compound CN1N=C(C(=C1)C=1C=C(C=CC=1)NCC1CN(CC1)C#N)C BONIFODIXPLUFS-UHFFFAOYSA-N 0.000 claims 1
- KUWMGOCZBMTZLF-UHFFFAOYSA-N 3-[[4-(1,3-dimethylpyrazol-4-yl)-2-fluoroanilino]methyl]pyrrolidine-1-carbonitrile Chemical compound CN1N=C(C(=C1)C1=CC(=C(C=C1)NCC1CN(CC1)C#N)F)C KUWMGOCZBMTZLF-UHFFFAOYSA-N 0.000 claims 1
- XMWFANXRRULTGY-UHFFFAOYSA-N 3-[[4-(1,3-dimethylpyrazol-4-yl)anilino]methyl]pyrrolidine-1-carbonitrile Chemical compound CN1N=C(C(=C1)C1=CC=C(C=C1)NCC1CN(CC1)C#N)C XMWFANXRRULTGY-UHFFFAOYSA-N 0.000 claims 1
- RRIKZZZOBXOTDM-UHFFFAOYSA-N 3-[[[2-(1,3-dihydroisoindol-2-yl)pyridin-4-yl]amino]methyl]pyrrolidine-1-carbonitrile Chemical compound C1N(CC2=CC=CC=C12)C1=NC=CC(=C1)NCC1CN(CC1)C#N RRIKZZZOBXOTDM-UHFFFAOYSA-N 0.000 claims 1
- VJVXZMAKWGNQQY-UHFFFAOYSA-N 3-[[[6-(1H-pyrazol-4-yl)-1,3-benzothiazol-2-yl]amino]methyl]pyrrolidine-1-carbonitrile Chemical compound N1N=CC(=C1)C1=CC2=C(N=C(S2)NCC2CN(CC2)C#N)C=C1 VJVXZMAKWGNQQY-UHFFFAOYSA-N 0.000 claims 1
- 208000009270 3-hydroxyacyl-CoA dehydrogenase deficiency Diseases 0.000 claims 1
- QNYCWDMDRKCZIS-GFCCVEGCSA-N 5-(3-cyanophenyl)-N-[[(3R)-1-cyanopyrrolidin-3-yl]methyl]-1,3,4-oxadiazole-2-carboxamide Chemical compound C(#N)C=1C=C(C=CC=1)C1=NN=C(O1)C(=O)NC[C@@H]1CN(CC1)C#N QNYCWDMDRKCZIS-GFCCVEGCSA-N 0.000 claims 1
- QNYCWDMDRKCZIS-LBPRGKRZSA-N 5-(3-cyanophenyl)-N-[[(3S)-1-cyanopyrrolidin-3-yl]methyl]-1,3,4-oxadiazole-2-carboxamide Chemical compound O=C(NC[C@@H]1CCN(C1)C#N)C1=NN=C(O1)C1=CC(=CC=C1)C#N QNYCWDMDRKCZIS-LBPRGKRZSA-N 0.000 claims 1
- DBDLNSFTJIEYFE-SNVBAGLBSA-N 6-chloro-N-[[(3R)-1-cyanopyrrolidin-3-yl]methyl]imidazo[1,2-a]pyridine-2-carboxamide Chemical compound ClC1=CN2C=C(N=C2C=C1)C(=O)NC[C@H]1CCN(C1)C#N DBDLNSFTJIEYFE-SNVBAGLBSA-N 0.000 claims 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 1
- GXBHHKRJFXMETN-SNVBAGLBSA-N 7-chloro-N-[[(3R)-1-cyanopyrrolidin-3-yl]methyl]imidazo[1,2-a]pyridine-2-carboxamide Chemical compound ClC1=CC2=NC(=CN2C=C1)C(=O)NC[C@H]1CCN(C1)C#N GXBHHKRJFXMETN-SNVBAGLBSA-N 0.000 claims 1
- 102100026882 Alpha-synuclein Human genes 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 201000005943 Barth syndrome Diseases 0.000 claims 1
- 102000051485 Bcl-2 family Human genes 0.000 claims 1
- 108700038897 Bcl-2 family Proteins 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 201000002929 Carnitine palmitoyltransferase II deficiency Diseases 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 201000000915 Chronic Progressive External Ophthalmoplegia Diseases 0.000 claims 1
- 208000010354 Coenzyme Q10 deficiency Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000021075 Creatine deficiency syndrome Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 claims 1
- 102000015782 Electron Transport Complex III Human genes 0.000 claims 1
- 108010024882 Electron Transport Complex III Proteins 0.000 claims 1
- 208000032274 Encephalopathy Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 101000804964 Homo sapiens DNA polymerase subunit gamma-1 Proteins 0.000 claims 1
- 101000595929 Homo sapiens POLG alternative reading frame Proteins 0.000 claims 1
- 101000605835 Homo sapiens Serine/threonine-protein kinase PINK1, mitochondrial Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 102100030358 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Human genes 0.000 claims 1
- 101710150008 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Proteins 0.000 claims 1
- 208000006136 Leigh Disease Diseases 0.000 claims 1
- 208000017507 Leigh syndrome Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 108700006159 Long-chain acyl-CoA dehydrogenase deficiency Proteins 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 108700000232 Medium chain acyl CoA dehydrogenase deficiency Proteins 0.000 claims 1
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 claims 1
- 206010072928 Mucolipidosis type II Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000010428 Muscle Weakness Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims 1
- FVJOTUZVSOJFAZ-UHFFFAOYSA-N N-[(1-cyanopyrrolidin-3-yl)methyl]-2-phenyl-1,3-oxazole-5-carboxamide Chemical compound C(#N)N1CC(CC1)CNC(=O)C1=CN=C(O1)C1=CC=CC=C1 FVJOTUZVSOJFAZ-UHFFFAOYSA-N 0.000 claims 1
- SYQCTYIQOGDDGP-UHFFFAOYSA-N N-[(1-cyanopyrrolidin-3-yl)methyl]-2-phenyl-1,3-thiazole-4-carboxamide Chemical compound C(#N)N1CC(CC1)CNC(=O)C=1N=C(SC=1)C1=CC=CC=C1 SYQCTYIQOGDDGP-UHFFFAOYSA-N 0.000 claims 1
- ODNGJGWYCUPHDI-UHFFFAOYSA-N N-[(1-cyanopyrrolidin-3-yl)methyl]-3-(2-fluorophenyl)-1H-pyrazole-5-carboxamide Chemical compound C(#N)N1CC(CC1)CNC(=O)C1=CC(=NN1)C1=C(C=CC=C1)F ODNGJGWYCUPHDI-UHFFFAOYSA-N 0.000 claims 1
- YADVBEWRFDVFJO-UHFFFAOYSA-N N-[(1-cyanopyrrolidin-3-yl)methyl]-3-(2-methylphenyl)-1H-pyrazole-5-carboxamide Chemical compound C(#N)N1CC(CC1)CNC(=O)C1=CC(=NN1)C1=C(C=CC=C1)C YADVBEWRFDVFJO-UHFFFAOYSA-N 0.000 claims 1
- INMAXULWSCWODX-UHFFFAOYSA-N N-[(1-cyanopyrrolidin-3-yl)methyl]-3-phenyl-1,2-oxazole-5-carboxamide Chemical compound C(#N)N1CC(CC1)CNC(=O)C1=CC(=NO1)C1=CC=CC=C1 INMAXULWSCWODX-UHFFFAOYSA-N 0.000 claims 1
- ICGHGMIENXBPDK-UHFFFAOYSA-N N-[(1-cyanopyrrolidin-3-yl)methyl]-3-phenyl-1H-pyrazole-5-carboxamide Chemical compound C(#N)N1CC(CC1)CNC(=O)C1=NNC(=C1)C1=CC=CC=C1 ICGHGMIENXBPDK-UHFFFAOYSA-N 0.000 claims 1
- KQSNHUUEHQGKGE-UHFFFAOYSA-N N-[(1-cyanopyrrolidin-3-yl)methyl]-4-(phenylsulfamoyl)benzamide Chemical compound C(#N)N1CC(CC1)CNC(C1=CC=C(C=C1)S(NC1=CC=CC=C1)(=O)=O)=O KQSNHUUEHQGKGE-UHFFFAOYSA-N 0.000 claims 1
- XSXXCNSCJZUFFB-UHFFFAOYSA-N N-[(1-cyanopyrrolidin-3-yl)methyl]-4-[5-(trifluoromethyl)pyridin-2-yl]oxybenzenesulfonamide Chemical compound FC(F)(F)c1ccc(Oc2ccc(cc2)S(=O)(=O)NCC2CCN(C2)C#N)nc1 XSXXCNSCJZUFFB-UHFFFAOYSA-N 0.000 claims 1
- QYDVNMCMIBEURQ-UHFFFAOYSA-N N-[(1-cyanopyrrolidin-3-yl)methyl]-4-methyl-3-oxo-1,4-benzoxazine-6-carboxamide Chemical compound C(#N)N1CC(CC1)CNC(=O)C1=CC2=C(OCC(N2C)=O)C=C1 QYDVNMCMIBEURQ-UHFFFAOYSA-N 0.000 claims 1
- TXVLWXPZJTWCGI-UHFFFAOYSA-N N-[(1-cyanopyrrolidin-3-yl)methyl]-4-pyridin-4-ylbenzamide Chemical compound C(#N)N1CC(CC1)CNC(C1=CC=C(C=C1)C1=CC=NC=C1)=O TXVLWXPZJTWCGI-UHFFFAOYSA-N 0.000 claims 1
- IHMFMCZUAYSYLG-UHFFFAOYSA-N N-[(1-cyanopyrrolidin-3-yl)methyl]-4-pyrrolidin-1-ylpyridine-2-carboxamide Chemical compound C(#N)N1CC(CC1)CNC(C1=NC=CC(=C1)N1CCCC1)=O IHMFMCZUAYSYLG-UHFFFAOYSA-N 0.000 claims 1
- UJSOQMOYAGSTKL-UHFFFAOYSA-N N-[(1-cyanopyrrolidin-3-yl)methyl]-5-(4-fluorophenyl)pyridine-3-carboxamide Chemical compound C(#N)N1CC(CC1)CNC(C1=CN=CC(=C1)C1=CC=C(C=C1)F)=O UJSOQMOYAGSTKL-UHFFFAOYSA-N 0.000 claims 1
- WNAHDZPGZVLNKT-UHFFFAOYSA-N N-[(1-cyanopyrrolidin-3-yl)methyl]-5-phenyl-1,3-oxazole-2-carboxamide Chemical compound C(#N)N1CC(CC1)CNC(=O)C=1OC(=CN=1)C1=CC=CC=C1 WNAHDZPGZVLNKT-UHFFFAOYSA-N 0.000 claims 1
- AFCBARSMQIKDLZ-UHFFFAOYSA-N N-[(1-cyanopyrrolidin-3-yl)methyl]-6-(1-methylpyrazol-4-yl)imidazo[1,2-a]pyridine-2-carboxamide Chemical compound C(#N)N1CC(CC1)CNC(=O)C=1N=C2N(C=C(C=C2)C=2C=NN(C=2)C)C=1 AFCBARSMQIKDLZ-UHFFFAOYSA-N 0.000 claims 1
- IJTIBKOLPGKNJJ-UHFFFAOYSA-N N-[(1-cyanopyrrolidin-3-yl)methyl]-N-methyl-2-(4-phenylphenyl)acetamide Chemical compound C1(=CC=C(C=C1)CC(=O)N(C)CC1CN(CC1)C#N)C1=CC=CC=C1 IJTIBKOLPGKNJJ-UHFFFAOYSA-N 0.000 claims 1
- VTSBHEBQFJJENU-UHFFFAOYSA-N N-[(1-cyanopyrrolidin-3-yl)methyl]-N-methyl-3-(2-methyl-1,3-thiazol-4-yl)benzenesulfonamide Chemical compound C(#N)N1CC(CC1)CN(S(=O)(=O)C1=CC(=CC=C1)C=1N=C(SC=1)C)C VTSBHEBQFJJENU-UHFFFAOYSA-N 0.000 claims 1
- BKHZFTFJDYOETK-CYBMUJFWSA-N N-[[(3R)-1-cyanopyrrolidin-3-yl]methyl]-1-(2-methoxyphenyl)imidazole-4-carboxamide Chemical compound C(#N)N1C[C@H](CC1)CNC(=O)C=1N=CN(C=1)C1=C(C=CC=C1)OC BKHZFTFJDYOETK-CYBMUJFWSA-N 0.000 claims 1
- MIIUXEYSUBINKP-CYBMUJFWSA-N N-[[(3R)-1-cyanopyrrolidin-3-yl]methyl]-1-(3-methoxyphenyl)imidazole-4-carboxamide Chemical compound C(#N)N1C[C@H](CC1)CNC(=O)C=1N=CN(C=1)C1=CC(=CC=C1)OC MIIUXEYSUBINKP-CYBMUJFWSA-N 0.000 claims 1
- ZMYDRZWNHZKCMN-GFCCVEGCSA-N N-[[(3R)-1-cyanopyrrolidin-3-yl]methyl]-1-(cyclopropylmethyl)imidazole-4-carboxamide Chemical compound C(#N)N1C[C@H](CC1)CNC(=O)C=1N=CN(C=1)CC1CC1 ZMYDRZWNHZKCMN-GFCCVEGCSA-N 0.000 claims 1
- YYDACHPLTYKYGE-CYBMUJFWSA-N N-[[(3R)-1-cyanopyrrolidin-3-yl]methyl]-1-phenylimidazole-4-carboxamide Chemical compound C(#N)N1C[C@H](CC1)CNC(=O)C=1N=CN(C=1)C1=CC=CC=C1 YYDACHPLTYKYGE-CYBMUJFWSA-N 0.000 claims 1
- XTUZBRUXFUDTMK-CYBMUJFWSA-N N-[[(3R)-1-cyanopyrrolidin-3-yl]methyl]-1-phenylpyrazole-3-carboxamide Chemical compound C(#N)N1C[C@H](CC1)CNC(=O)C1=NN(C=C1)C1=CC=CC=C1 XTUZBRUXFUDTMK-CYBMUJFWSA-N 0.000 claims 1
- ALQSOZZAXIRFNS-SNVBAGLBSA-N N-[[(3R)-1-cyanopyrrolidin-3-yl]methyl]-1H-benzimidazole-2-carboxamide Chemical compound C(#N)N1C[C@H](CC1)CNC(=O)C1=NC2=C(N1)C=CC=C2 ALQSOZZAXIRFNS-SNVBAGLBSA-N 0.000 claims 1
- ZDVWDVSXNULHLW-GFCCVEGCSA-N N-[[(3R)-1-cyanopyrrolidin-3-yl]methyl]-2-phenyl-1H-imidazole-5-carboxamide Chemical compound C(#N)N1C[C@H](CC1)CNC(=O)C1=CN=C(N1)C1=CC=CC=C1 ZDVWDVSXNULHLW-GFCCVEGCSA-N 0.000 claims 1
- WXEFVGNMFMNWIM-GFCCVEGCSA-N N-[[(3R)-1-cyanopyrrolidin-3-yl]methyl]-4-phenyl-1,3-thiazole-2-carboxamide Chemical compound C(#N)N1C[C@H](CC1)CNC(=O)C=1SC=C(N=1)C1=CC=CC=C1 WXEFVGNMFMNWIM-GFCCVEGCSA-N 0.000 claims 1
- NGPOEDGDLYCPHF-CQSZACIVSA-N N-[[(3R)-1-cyanopyrrolidin-3-yl]methyl]-4-phenylpyridine-2-carboxamide Chemical compound C(#N)N1C[C@H](CC1)CNC(C1=NC=CC(=C1)C1=CC=CC=C1)=O NGPOEDGDLYCPHF-CQSZACIVSA-N 0.000 claims 1
- WZQZWLZAOZXBGK-GFCCVEGCSA-N N-[[(3R)-1-cyanopyrrolidin-3-yl]methyl]-5-phenyl-1,2-oxazole-3-carboxamide Chemical compound C(#N)N1C[C@H](CC1)CNC(=O)C1=NOC(=C1)C1=CC=CC=C1 WZQZWLZAOZXBGK-GFCCVEGCSA-N 0.000 claims 1
- NXWSDHWYAPPKQT-GFCCVEGCSA-N N-[[(3R)-1-cyanopyrrolidin-3-yl]methyl]-5-phenyl-1,3-thiazole-2-carboxamide Chemical compound C(#N)N1C[C@H](CC1)CNC(=O)C=1SC(=CN=1)C1=CC=CC=C1 NXWSDHWYAPPKQT-GFCCVEGCSA-N 0.000 claims 1
- LJLVDKFFRRWCNQ-CQSZACIVSA-N N-[[(3R)-1-cyanopyrrolidin-3-yl]methyl]-5-phenylpyridine-2-carboxamide Chemical compound C(#N)N1C[C@H](CC1)CNC(C1=NC=C(C=C1)C1=CC=CC=C1)=O LJLVDKFFRRWCNQ-CQSZACIVSA-N 0.000 claims 1
- ARRJGAKIYIHNTR-GFCCVEGCSA-N N-[[(3R)-1-cyanopyrrolidin-3-yl]methyl]-7-cyclopropylimidazo[1,2-a]pyridine-2-carboxamide Chemical compound C(#N)N1C[C@H](CC1)CNC(=O)C=1N=C2N(C=CC(=C2)C2CC2)C=1 ARRJGAKIYIHNTR-GFCCVEGCSA-N 0.000 claims 1
- WGISYTVANPICRV-GFCCVEGCSA-N N-[[(3R)-1-cyanopyrrolidin-3-yl]methyl]isoquinoline-3-carboxamide Chemical compound C(#N)N1C[C@H](CC1)CNC(=O)C=1N=CC2=CC=CC=C2C=1 WGISYTVANPICRV-GFCCVEGCSA-N 0.000 claims 1
- RUXMZIXKJFUCQK-LLVKDONJSA-N N-[[(3R)-1-cyanopyrrolidin-3-yl]methyl]pyrazolo[1,5-a]pyridine-2-carboxamide Chemical compound C(#N)N1C[C@H](CC1)CNC(=O)C1=NN2C(C=CC=C2)=C1 RUXMZIXKJFUCQK-LLVKDONJSA-N 0.000 claims 1
- VLSUKJWWCSVNNC-JTQLQIEISA-N N-[[(3S)-1-cyanopyrrolidin-3-yl]methyl]-3-oxo-4H-1,4-benzoxazine-6-carboxamide Chemical compound O=C(NC[C@@H]1CCN(C1)C#N)C1=CC2=C(OCC(=O)N2)C=C1 VLSUKJWWCSVNNC-JTQLQIEISA-N 0.000 claims 1
- 206010029333 Neurosis Diseases 0.000 claims 1
- 102100035196 POLG alternative reading frame Human genes 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 208000013234 Pearson syndrome Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000002009 Pyruvate Dehydrogenase Complex Deficiency Disease Diseases 0.000 claims 1
- 208000021886 Pyruvate carboxylase deficiency Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 102100038376 Serine/threonine-protein kinase PINK1, mitochondrial Human genes 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 108090000185 alpha-Synuclein Proteins 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000005775 apoptotic pathway Effects 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 201000008609 cerebral creatine deficiency syndrome Diseases 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000009028 early myoclonic encephalopathy Diseases 0.000 claims 1
- 210000001652 frontal lobe Anatomy 0.000 claims 1
- QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 208000014188 hereditary optic neuropathy Diseases 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims 1
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 231100000518 lethal Toxicity 0.000 claims 1
- 230000001665 lethal effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000004687 long chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000005548 medium chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 201000002697 mitochondrial DNA depletion syndrome Diseases 0.000 claims 1
- 230000004065 mitochondrial dysfunction Effects 0.000 claims 1
- 208000020460 mucolipidosis II alpha/beta Diseases 0.000 claims 1
- 208000020468 mucolipidosis III alpha/beta Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000015238 neurotic disease Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 108010007425 oligomycin sensitivity conferring protein Proteins 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 201000006473 pyruvate decarboxylase deficiency Diseases 0.000 claims 1
- 208000015445 pyruvate dehydrogenase deficiency Diseases 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1522267.2A GB201522267D0 (en) | 2015-12-17 | 2015-12-17 | Novel compounds |
| GB1522267.2 | 2015-12-17 | ||
| PCT/GB2016/053971 WO2017103614A1 (en) | 2015-12-17 | 2016-12-16 | Novel Compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019504009A JP2019504009A (ja) | 2019-02-14 |
| JP2019504009A5 true JP2019504009A5 (enExample) | 2020-02-06 |
| JP6898327B2 JP6898327B2 (ja) | 2021-07-07 |
Family
ID=55311125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531219A Active JP6898327B2 (ja) | 2015-12-17 | 2016-12-16 | 新規化合物 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11130748B2 (enExample) |
| EP (2) | EP3390391B1 (enExample) |
| JP (1) | JP6898327B2 (enExample) |
| KR (1) | KR102663994B1 (enExample) |
| CN (1) | CN108368089B (enExample) |
| AU (1) | AU2016373533B2 (enExample) |
| BR (1) | BR112018007208B1 (enExample) |
| CA (1) | CA3008747C (enExample) |
| CO (1) | CO2018006299A2 (enExample) |
| ES (1) | ES2929376T3 (enExample) |
| GB (1) | GB201522267D0 (enExample) |
| IL (1) | IL258444B (enExample) |
| MA (1) | MA44050A (enExample) |
| MX (1) | MX387482B (enExample) |
| MY (1) | MY196729A (enExample) |
| RU (1) | RU2734256C2 (enExample) |
| SG (1) | SG11201804934PA (enExample) |
| WO (1) | WO2017103614A1 (enExample) |
| ZA (1) | ZA201804739B (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20210791T2 (hr) | 2015-03-30 | 2021-12-10 | Mission Therapeutics Limited | 1-cijano-pirolidin spojevi kao usp30 inhibitori |
| CN107849013B (zh) | 2015-07-14 | 2022-03-29 | 特殊治疗有限公司 | 作为dub抑制剂用于治疗癌症的氰基吡咯烷类 |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) * | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) * | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| EP3433246B1 (en) | 2016-03-24 | 2022-05-04 | Mission Therapeutics Limited | 1-cyano-pyrrolidine derivatives as dbu inhibitors |
| ES2850349T3 (es) | 2016-09-27 | 2021-08-27 | Mission Therapeutics Ltd | Derivados de cianopirrolidina con actividad como inhibidores de USP30 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) * | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
| CN110831936B (zh) * | 2017-06-20 | 2023-03-28 | 特殊治疗有限公司 | 具有dub抑制剂活性的取代氰基吡咯烷 |
| WO2019071073A1 (en) * | 2017-10-06 | 2019-04-11 | Forma Therapeutics, Inc. | INHIBITION OF THE SPECIFIC PEPTIDASE OF UBIQUITIN |
| GB2571731A (en) * | 2018-03-06 | 2019-09-11 | Mission Therapeutics Ltd | Novel compounds and uses |
| WO2019180686A1 (en) * | 2018-03-23 | 2019-09-26 | Cmg Pharmaceutical Co., Ltd. | Ido-tdo dual inhibitor and related methods of use |
| ES2988920T3 (es) * | 2018-05-17 | 2024-11-22 | Forma Therapeutics Inc | Compuestos bicíclicos fusionados útiles como inhibidores de la peptidasa 30 específica de ubiquitina |
| WO2020033709A1 (en) | 2018-08-09 | 2020-02-13 | Forma Therapeutics, Inc. | Inhibiting deubiquitinase usp25 and usp28 |
| JP7434285B2 (ja) | 2018-08-14 | 2024-02-20 | アムジエン・インコーポレーテツド | Ｎ－シアノ－７－アザノルボルナン誘導体及びその使用 |
| AU2019356011B2 (en) * | 2018-10-05 | 2025-02-06 | Forma Therapeutics, Inc. | Fused pyrrolines which act as Ubiquitin-Specific Protease 30 (USP30) inhibitors |
| GB201905371D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201912674D0 (en) * | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
| WO2021200934A1 (ja) * | 2020-03-30 | 2021-10-07 | 国立大学法人 長崎大学 | 抗マラリア薬 |
| MX2022012578A (es) | 2020-04-08 | 2022-11-07 | Mission Therapeutics Ltd | N-cianopirrolidinas con actividad como inhibidores de usp30. |
| EP4157834B1 (en) * | 2020-05-28 | 2024-07-03 | Mission Therapeutics Limited | N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction |
| IL298710A (en) * | 2020-06-04 | 2023-02-01 | Mission Therapeutics Ltd | N-cyanopyrrolidines with activity as USP30 inhibitors |
| KR20230022215A (ko) | 2020-06-08 | 2023-02-14 | 미션 테라퓨틱스 엘티디 | 미토콘드리아 기능장애, 암 및 섬유증의 치료에 사용하기 위한 USP30 억제제로서 1-(5-(2-시아노피리딘-4-일)옥사졸-2-카보닐)-4-메틸헥사하이드로피롤로[3,4-b]피롤-5(1H)-카보니트릴 |
| GB202016800D0 (en) | 2020-10-22 | 2020-12-09 | Mission Therapeutics Ltd | Novel compounds |
| WO2023099561A1 (en) | 2021-12-01 | 2023-06-08 | Mission Therapeutics Limited | Substituted n-cyanopyrrolidines with activity as usp30 inhibitors |
| GB202408928D0 (en) | 2024-06-21 | 2024-08-07 | Mission Therapeutics Ltd | Novel compounds |
| GB202411060D0 (en) | 2024-07-29 | 2024-09-11 | Mission Therapeutics Ltd | Novel compounds |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001077073A1 (en) * | 2000-04-06 | 2001-10-18 | Merck Frosst Canada & Co. | Cathepsin cysteine protease inhibitors |
| EP2133331A4 (en) * | 2007-04-11 | 2011-06-22 | Kissei Pharmaceutical | FIVE-GLASS HETEROCYCLIC DERIVATIVE AND ITS USE IN MEDICAL PURPOSES |
| EP2565186A1 (en) * | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| WO2015179190A1 (en) * | 2014-05-19 | 2015-11-26 | Northeastern University | N-acylethanolamine hydrolyzing acid amidase (naaa) inhibitors and their use thereof |
| GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| HRP20210791T2 (hr) | 2015-03-30 | 2021-12-10 | Mission Therapeutics Limited | 1-cijano-pirolidin spojevi kao usp30 inhibitori |
| CN107849013B (zh) | 2015-07-14 | 2022-03-29 | 特殊治疗有限公司 | 作为dub抑制剂用于治疗癌症的氰基吡咯烷类 |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) * | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) * | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| EP3433246B1 (en) | 2016-03-24 | 2022-05-04 | Mission Therapeutics Limited | 1-cyano-pyrrolidine derivatives as dbu inhibitors |
| ES2850349T3 (es) * | 2016-09-27 | 2021-08-27 | Mission Therapeutics Ltd | Derivados de cianopirrolidina con actividad como inhibidores de USP30 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| CN110831936B (zh) * | 2017-06-20 | 2023-03-28 | 特殊治疗有限公司 | 具有dub抑制剂活性的取代氰基吡咯烷 |
-
2015
- 2015-12-17 GB GBGB1522267.2A patent/GB201522267D0/en not_active Ceased
-
2016
- 2016-12-16 RU RU2018123779A patent/RU2734256C2/ru active
- 2016-12-16 AU AU2016373533A patent/AU2016373533B2/en active Active
- 2016-12-16 MA MA044050A patent/MA44050A/fr unknown
- 2016-12-16 CA CA3008747A patent/CA3008747C/en active Active
- 2016-12-16 MY MYPI2018000546A patent/MY196729A/en unknown
- 2016-12-16 BR BR112018007208-7A patent/BR112018007208B1/pt active IP Right Grant
- 2016-12-16 CN CN201680073270.2A patent/CN108368089B/zh active Active
- 2016-12-16 KR KR1020187020277A patent/KR102663994B1/ko active Active
- 2016-12-16 US US15/781,615 patent/US11130748B2/en active Active
- 2016-12-16 ES ES16816365T patent/ES2929376T3/es active Active
- 2016-12-16 WO PCT/GB2016/053971 patent/WO2017103614A1/en not_active Ceased
- 2016-12-16 MX MX2018007449A patent/MX387482B/es unknown
- 2016-12-16 EP EP16816365.7A patent/EP3390391B1/en active Active
- 2016-12-16 SG SG11201804934PA patent/SG11201804934PA/en unknown
- 2016-12-16 JP JP2018531219A patent/JP6898327B2/ja active Active
- 2016-12-16 EP EP22195076.9A patent/EP4122929A1/en not_active Withdrawn
-
2018
- 2018-03-28 IL IL258444A patent/IL258444B/en active IP Right Grant
- 2018-06-18 CO CONC2018/0006299A patent/CO2018006299A2/es unknown
- 2018-07-16 ZA ZA2018/04739A patent/ZA201804739B/en unknown
-
2021
- 2021-08-16 US US17/402,802 patent/US11958833B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019504009A5 (enExample) | ||
| JP2018524367A5 (enExample) | ||
| JP2019501142A5 (enExample) | ||
| JP2018510183A5 (enExample) | ||
| JP7216682B2 (ja) | Ｕｓｐ３０阻害剤としての１－シアノ－ピロリジン化合物 | |
| US12065436B2 (en) | Cardiac sarcomere inhibitors | |
| JP2019513135A5 (enExample) | ||
| JP2020521730A5 (enExample) | ||
| JP2019533659A5 (enExample) | ||
| JP5055136B2 (ja) | Ｖｅｇｆ−ｒ２阻害剤としてのイミダゾ（１，２−ａ）ピリジン化合物 | |
| JP2019509274A5 (enExample) | ||
| JP2016522246A5 (enExample) | ||
| JP2017512794A5 (enExample) | ||
| JP2019532950A5 (enExample) | ||
| JP2017532360A5 (enExample) | ||
| JP2022546717A (ja) | Ｕｓｐ３０阻害剤としての活性を有する置換シアノピロリジン類 | |
| JP2007510689A5 (enExample) | ||
| RU2017105296A (ru) | Новые соединения | |
| HRP20201469T1 (hr) | Derivati tetrahidroizokinolina | |
| BG107632A (bg) | Пиридинови производни с ikb-киназна (ikk-бета) инхибираща активност | |
| JP2017530185A5 (enExample) | ||
| JP2013529652A (ja) | 複素環アルキニルベンゼン化合物と、その医療用組成物および使用 | |
| JP2017508766A5 (enExample) | ||
| US20200405697A1 (en) | Antitumor Agent | |
| JP2017528515A5 (enExample) |